These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30766008)

  • 1. Pharmaceutical Approval Update.
    Kaufman MB
    P T; 2019 Jan; 44(2):42-44. PubMed ID: 30766008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 Apr; 79(5):555-562. PubMed ID: 30877642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xofluza (Baloxavir Marboxil) for the Treatment Of Acute Uncomplicated Influenza.
    Ng KE
    P T; 2019 Jan; 44(1):9-11. PubMed ID: 30675086
    [No Abstract]   [Full Text] [Related]  

  • 4. Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex.
    Swenson C; Del Parigi A
    Mayo Clin Proc; 2020 Jan; 95(1):201-202. PubMed ID: 31902419
    [No Abstract]   [Full Text] [Related]  

  • 5. In reply-Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex.
    Shulha J
    Mayo Clin Proc; 2020 Jan; 95(1):202. PubMed ID: 31902420
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
    Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
    J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
    Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 May; 79(7):791. PubMed ID: 30941606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.
    Locke SC; Splawn LM; Cho JC
    Drugs Today (Barc); 2019 Jun; 55(6):359-366. PubMed ID: 31250840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omadacycline (Nuzyra)--a new tetracycline antibiotic.
    Med Lett Drugs Ther; 2019 May; 61(1572):74-77. PubMed ID: 31169800
    [No Abstract]   [Full Text] [Related]  

  • 11. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baloxavir marboxil (Xofluza) for treatment of influenza.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):193-196. PubMed ID: 30653474
    [No Abstract]   [Full Text] [Related]  

  • 13. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines.
    Durães F; Sousa E
    Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 31010063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies.
    Sakoulas G; Eckburg PB; Amodio-Groton M; Manley A; Tzanis E; Das AF; Noble R; McGovern PC
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab136. PubMed ID: 34160473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baloxavir marboxil: the new influenza drug on the market.
    O'Hanlon R; Shaw ML
    Curr Opin Virol; 2019 Apr; 35():14-18. PubMed ID: 30852344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory
    Marras TK; Hassan M; Mange KC; Ciesielska M; Murthy SD; Jumadilova Z; Chatterjee A
    ERJ Open Res; 2022 Jul; 8(3):. PubMed ID: 35821755
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
    Kiso M; Yamayoshi S; Furusawa Y; Imai M; Kawaoka Y
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31731678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baloxavir Marboxil (Xofluza) for Influenza.
    Erlich DR
    Am Fam Physician; 2019 Dec; 100(12):776-777. PubMed ID: 31845775
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.
    Koshimichi H; Ishibashi T; Kawaguchi N; Sato C; Kawasaki A; Wajima T
    Clin Drug Investig; 2018 Dec; 38(12):1189-1196. PubMed ID: 30288682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?
    Daley CL; Olivier KN
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1473-1475. PubMed ID: 30365392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.